Related Experiment Video

Updated: Jun 12, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Dissecting variability in responses to cancer chemotherapy through systems pharmacology

R Yang1, M Niepel, T K Mitchison

  • 1Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|June 4, 2010
PubMed

Insights

Patient response variability to targeted therapies presents a major challenge. A systems pharmacology approach offers a quantitative, mechanistic framework to understand drug resistance, improving future therapeutics.

Area of Science:

  • Pharmacology
  • Systems Biology
  • Genomics

Background:

  • Patient response variability to targeted therapeutics is a significant challenge in oncology and immune therapy.
  • Mechanisms of drug resistance emerge in both naive and initially responsive patients.
  • Current preclinical studies are narrowly focused, hindering a comprehensive understanding of response determinants.

Purpose of the Study:

  • To introduce a systems pharmacology approach to address limitations in current mechanistic pharmacology.
  • To provide a quantitative, mechanistic, and probabilistic framework for understanding drug response variability.
  • To highlight the potential of systems pharmacology in postgenomic drug discovery.

Main Methods:

  • Focus on cell line studies as a model for mechanistic analysis.
  • Application of a systems pharmacology framework.
  • Integration of quantitative, probabilistic, and mechanistic principles.

Main Results:

  • The proposed systems pharmacology approach is mechanistic, quantitative, and probabilistic.
  • This approach promises to advance mechanistic pharmacology similarly to how genomics advanced correlative studies.
  • The framework is applicable to cell lines, xenografts, and potentially human studies.

Conclusions:

  • Systems pharmacology offers a powerful approach to unraveling drug response variability.
  • This methodology can overcome the limitations of narrowly focused preclinical studies.
  • It paves the way for improved drug discovery and patient care in oncology and immune therapy.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...